Quick Answer
Sigyn Therapeutics, Inc. reported Total Revenue of $143.3 thousand for the year ending 2019.
- Sigyn Therapeutics, Inc. showed an increase of +405.6% in Total Revenue from 2018 to 2019.
- This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2020.
- XBRL data for this metric is available from 2017 to 2019 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $268.9 thousand | Q2 2017: $432.5 thousand | Q3 2017: $256.0 thousand | Q1 2018: $23.1 thousand | Q2 2018: $5.8 thousand | Q3 2018: $90.5 thousand | Q1 2019: $41.6 thousand | Q2 2019: $64.3 thousand | Q3 2019: $32.1 thousand | Q1 2020: $756.00 | Q3 2020: $3.8 thousand.
- Over the full 3 years of available data (2017 to 2019), Sigyn Therapeutics, Inc.'s Total Revenue has grown by 272.9%.
- Historical annual values: Fiscal year 2019: $143.3 thousand | Fiscal year 2018: $28.3 thousand | Fiscal year 2017: $38.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: